Montserrat Andrade Detrell
Director/Board Member bei PHARMA MAR, S.A.
Vermögen: 30 Mio $ am 31.03.2024
Profil
Montserrat Andrade Detrell is currently the Director at Pharma Mar SA and a Member at Sociedad Española de Senología y Patología Mamaria.
Previously, she worked as the Head-Institutional Relations at Zeltia SA from 2007 to 2012.
Dr. Andrade Detrell has an undergraduate degree from Universidad Complutense de Madrid, a doctorate degree from Universidad Complutense de Madrid, a graduate degree from the University of Strasbourg, a doctorate degree from University Carlos III of Madrid, and a graduate degree from the University of Barcelona.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PHARMA MAR SA
5,14% | 13.06.2023 | 954 460 ( 5,14% ) | 30 Mio $ | 31.03.2024 |
Aktive Positionen von Montserrat Andrade Detrell
| Unternehmen | Position | Beginn |
|---|---|---|
| PHARMA MAR, S.A. | Director/Board Member | - |
| Sociedad Española de Senología y Patología Mamaria | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Montserrat Andrade Detrell
| Unternehmen | Position | Ende |
|---|---|---|
| ZELTIA SA | Corporate Officer/Principal | 01.01.2012 |
Ausbildung von Montserrat Andrade Detrell
| Universidad Complutense de Madrid | Undergraduate Degree |
| University of Barcelona | Graduate Degree |
| University of Strasbourg | Graduate Degree |
| University Carlos III of Madrid | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PHARMA MAR, S.A. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Zeltia SA
 Zeltia SA BiotechnologyHealth Technology Zeltia SA is a holding company, which develops marine-based drugs in the field of oncology. It operates through the Biopharmaceuticals and Consumer Chemicals segments. The Biopharmaceuticals segment engages in the research and marketing of anti-tumor drugs, diagnosis kits, and development of therapies based on reducing or silencing gene expression. The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and related products. The company was founded on August 3, 1939 and is headquartered in Madrid, Spain. | Health Technology |
| Sociedad Española de Senología y Patología Mamaria |
